Research and Development, Inova Diagnostics , San Diego , CA , USA.
Department of Experimental Science, Francisco de Vitoria University , Madrid , Spain.
Expert Rev Clin Immunol. 2019 Oct;15(10):1073-1087. doi: 10.1080/1744666X.2020.1668778. Epub 2019 Oct 13.
: The protein-arginine deiminase (PAD) 4 enzyme plays an important role in the pathogenesis of rheumatoid arthritis (RA) and also represents an antigenic target. Anti-PAD4 antibodies can be present in RA and are associated with specific clinical features. : This review aims to analyze the current knowledge and recent findings on anti-PAD4 antibodies in RA and their clinical and immunological significance. : Anti-PAD4 antibodies are not currently used in clinical practice for the management of RA. Nevertheless, there is growing evidence of their relevance in RA, and of their potential utility to improve diagnosis, patient stratification, and prognosis.
: 蛋白质精氨酸脱亚氨酶(PAD)4 酶在类风湿关节炎(RA)的发病机制中起着重要作用,也是一个抗原靶点。抗 PAD4 抗体可存在于 RA 中,并与特定的临床特征相关。: 本综述旨在分析 RA 中抗 PAD4 抗体的现有知识和最新发现,以及它们的临床和免疫学意义。: 抗 PAD4 抗体目前尚未用于 RA 的临床管理。然而,越来越多的证据表明它们在 RA 中具有相关性,并且有可能用于改善诊断、患者分层和预后。